|
Dec 16, 2024
|
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
|
|
|
Nov 26, 2024
|
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
|
|
|
Nov 12, 2024
|
Innoviva to Participate in the UBS Global Healthcare Conference
|
|
|
Nov 06, 2024
|
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
|
|
|
Sep 04, 2024
|
Innoviva to Participate in Upcoming Investor Conferences
|
|
|
Jul 31, 2024
|
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
|
|
|
Jun 03, 2024
|
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
|
|
May 20, 2024
|
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
|
|
|
May 08, 2024
|
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
|
|
|
May 08, 2024
|
Innoviva to Participate in the BofA Securities Health Care Conference
|
|